ArticlePloS one2025
Dealing with radiation risks in systemic cancer treatment: Perspectives of practitioners and patients in French hospitals.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Navigating care: understanding cancer patients' experiences with systemic radionuclide therapy.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic radionuclide therapy (SRT) using substances such as 177Lu is an approach in cancer treatment that aims to destroy malign tissues by injecting radionuclides directly into patients' bodies via the bloodstream. This treatment connects benefits of care with risks related to radioactivity. Our research conducted in French hospitals shows that managing risk is an integral part of SRT, spanning from implementation, hospitals' protocols, specific management, hospital settings, and training, to the individual experiences of health professionals and patients who are both exposed to radioactivity. This article argues that understanding how risks are managed in SRT not only requires making them identifiable, quantifiable, and calculable through medical devices in the context of evidence-based medicine, but also necessitates fostering trust throughout the treatment. This article explores and provides insights into three intertwined dimensions of trust in risk management: epistemic, (inter)-organizational, and interpersonal.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.